Gout Therapeutics Market Report Scope & Overview:

The Gout Therapeutics Market was valued at USD 3.00 Billion in 2025 and is expected to reach USD 5.74 Billion by 2035, growing at a CAGR of 6.72% from 2026–2035.

Gout is one form of an inflammatory disease affecting the joints and characterized by the creation of uric acid crystals, which can be further classified as either acute or chronic forms, depending on whether the condition requires urgent treatment or long-term care, respectively. While nonsteroidal anti-inflammatory medicines, corticosteroids, and colchicine help with the acute type, reduction of uric acid medicines like allopurinol, febuxostat, and biologics like pegloticase are useful in treating the chronic one. Some of the factors leading to gout are obesity, intake of foods containing purines, and old age diseases, causing more cases in the developed countries and helping the market grow. The introduction of biologics has greatly helped in meeting patients’ needs through medicines.

June 2024 witnessed AbbVie's acquisition of Celsius Therapeutics, a biotech firm based in Cambridge, Massachusetts, in a cash-only deal worth USD 250 million. With CEL383 being the first-in-class investigational compound under development by Celsius, AbbVie has brought under its wing another molecule to its inflammatory disease pipeline which includes gout, among others.

Market Size and Forecast

• Market Size in 2026E: USD 3.20 Billion

• Market Size by 2035: USD 5.74 Billion

• CAGR: 6.72% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Gout Therapeutics Market Trends

• Biologic therapies such as pegloticase and IL-1β inhibitors are gaining adoption for refractory gout despite high treatment costs.

• Combination treatment regimens using urate-lowering drugs with anti-inflammatory agents are improving flare control and long-term disease management.

• Biosimilar development is increasing after patent expirations of key biologics, improving affordability and access to advanced gout therapies.

• Novel URAT1 inhibitors and next-generation xanthine oxidase inhibitors are progressing in clinical pipelines, enhancing future treatment options.

• Improved diagnosis rates and public health awareness are expanding the treated gout patient population globally.

The U.S. Gout Therapeutics Market Outlook

The U.S. Gout Therapeutics Market was valued at approximately USD 1.12 Billion in 2025 and is expected to reach approximately USD 2.09 Billion by 2035, growing at a CAGR of approximately 6.43%.

The United States dominates the North American gout therapeutics market, with a share of nearly 78% of regional revenue. This dominance is fueled by a high incidence of gout, combined with strong healthcare infrastructure and enormous investment in R&D for advanced treatments. The United States has also been benefited from the fact that there have been large pharmaceutical companies and use of biological drugs like pegloticase and IL-1β antagonists. Favorable reimbursement policies and awareness programs regarding gout management are further helping the country stay ahead in this therapy segment.

FDA gives its approval to Gloperba 0.6 mg colchicine oral solution for the prevention of gout flares in adult patients in August 2024. This is an additional approval to the previous approval of this medicine in the form of an oral solution in 2019. The latest approval comes with clear guidance on how to use this product in certain conditions and drug interactions.

Gout Therapeutics Market Segment Analysis

• By Drug Class, the NSAIDs segment dominated the gout therapeutics market with a 44.15% revenue share in 2025, while urate-lowering agents is expected to grow fastest.

• By Disease Condition, the acute gout segment dominated the gout therapeutics market with a 66.43% revenue share in 2025, while chronic gout is expected to grow fastest.

• By Route of Administration, the oral segment dominated the gout therapeutics market with approximately 65.26% share in 2025, while is expected to grow fastest.

• By Distribution Channel, the retail pharmacy segment dominated the gout therapeutics market with approximately 68.14% share in 2025, and is also expected to grow fastest.

By Drug Class, NSAIDs dominate, urate-lowering agents grows fastest

The NSAID drugs had a market share of around 44.15% in the year 2025 because of their ease of access, fast relief of symptoms, and their being the primary option for managing acute gout episodes since a long time now. Drugs such as naproxen, indomethacin, and ibuprofen are generally prescribed or available as an OTC drug for treating inflammation as well as relieving the severe pain in joints due to deposition of urate crystals in the joint area.

Urate-lowering agents, including allopurinol, febuxostat, and newer biologics like pegloticase, represent the segment with the most active innovation, as they address the chronic underlying condition rather than just symptomatic relief. As biosimilar competition increases and newer agents like selective URAT1 inhibitors advance through clinical development, this drug class is positioned to see the most meaningful new product activity over the forecast period even though NSAIDs retain the largest current revenue share.

By Disease Condition, acute gout dominates, chronic gout grows fastest

Acute gout was responsible for nearly 66.43% of the market share in 2025 because of the incidence of rapid and sudden gout attacks that necessitate immediate treatment. Intense swelling of the joint, particularly the big toe, may have significant impacts on the quality of life of the patient, leading the patient to resort to immediate treatment by means of anti-inflammatory medications like NSAIDs, corticosteroids, and colchicine.

The chronic gout, recurring nature of acute gout attacks drives repeated healthcare visits and steady pharmaceutical demand, reinforcing this segment's leadership. As awareness has increased and diagnosis has become more accurate and timelier, the number of treated acute cases has continued to lead chronic management initiatives, though the two categories work together across a patient's overall treatment journey.

By Route of Administration, oral dominates and grows fastest

Oral mode of delivery held a huge chunk of the market share in 2025, accounting for nearly 65.26% of the market due to the convenience, affordability, and easy availability of oral drugs such as NSAIDs, colchicine, and uricosuric drugs like allopurinol and febuxostat. Patients opt for oral medication owing to their ability to be self-administered without healthcare supervision during acute and chronic gout attacks.

Generally, oral drugs are mostly recommended by physicians due to the proven effectiveness and safety associated with them, and the patient compliance factor also contributes in favor of this mode of drug administration, owing to the fact that oral drugs are more acceptable to patients than parenteral drugs. Parenteral mode of drug delivery is essential for biologics such as pegloticase because they cannot be taken orally, however; oral drugs still remain the preferred mode.

By Distribution Channel, retail pharmacy dominates and grows fastest

Retail pharmacy held about 68.14% of the market in 2025, largely due to the ready availability and accessibility of gout drugs including NSAIDs, colchicine, and urate-lowering medications in retail pharmacy stores. Patients generally prefer retail pharmacies for their convenience, longer operating hours, and the fact that prescriptions can be filled without a hospital visit.

The use of automated systems in retail pharmacies to handle insurance claims and billing in the process has further improved the purchasing process, resulting in patient satisfaction and adherence. This accessibility and efficiency of administration has made retail pharmacies the most desirable route of delivery for gout medication despite the increase in the use of online pharmacies.

Regional Analysis

North America Gout Therapeutics Market Insights

The North American region has been dominating the global market for gout therapeutics in 2025 with a significant market share of 48.20%, attributed primarily to the high prevalence of gout disease, existing healthcare system in the region, and the involvement of well-renowned drug companies such as Horizon Therapeutics, Takeda, and Amgen. Backed by strong clinical studies and regulatory approvals from agencies like the FDA, the North American region has witnessed an increasing adoption of advanced treatment therapies.

Favorable reimbursement policies and increased awareness of disease management have accelerated patient access to effective treatments across the region. The United States, in particular, holds a significant portion of regional revenue given its large gout patient population and steady innovation in treatment options, a position that's expected to keep North America as the largest regional market through the forecast period.

Europe Gout Therapeutics Market Insights

Europe is a very matured market for gout therapies because of the existence of very advanced healthcare infrastructures and regulations that facilitate quick access to generic and proprietary products. The leading player in this region, especially in terms of sales, is Germany which takes advantage of its older and developed rheumatology healthcare facilities.

The United Kingdom, France, and Italy round out regional demand, supported by public health systems that provide broad access to first-line NSAID and colchicine treatments alongside urate-lowering therapies. Continued investment in biosimilar development across the EU is expected to improve affordability and expand biologic access for patients with treatment-refractory gout across the region.

Asia Pacific Gout Therapeutics Market Insights

Asia Pacific is expected to show the fastest growth over the forecast period, at a CAGR of about 7.38%, as a growing geriatric population, rising gout incidence linked to lifestyle changes, and increasing access to healthcare services combine to accelerate market expansion. Improved diagnosis rates and rising demand for affordable treatment options are being observed across countries including China, Japan, and India.

Local manufacturing capabilities and the introduction of generic formulations are lowering treatment costs throughout the region, expanding access for a broader patient population. Government programs aimed at improving chronic disease management, along with rising investment in regional clinical trials by multinational pharmaceutical companies, are expected to keep fueling market expansion across Asia Pacific in the years ahead.

MEA & Latin America Gout Therapeutics Market Insights

The Middle East and Africa remain a developing gout therapeutics market, with demand tied to rising rates of metabolic syndrome and improving healthcare access across the region. Saudi Arabia is the dominant market among the countries in question due to its investment in healthcare infrastructure and rising diagnostic rates associated with its health sector reforms, while South Africa has an impact because of its already developed drug distribution system.

Latin America is experiencing consistent growth driven by Brazil, where obesity and availability of healthcare facilities have increased the number of patients suffering from gout in the country. The second largest market in Latin America is Mexico, where increasing production of generics and availability of public health care services are the major driving factors.

Market Dynamics

Growth Drivers: Rising gout prevalence and advancements in treatment options

The growing incidence of gout, mainly due to lifestyle factors including inappropriate diet, inactive lifestyles, and rising obesity levels, is a primary force behind gout therapeutics market growth. In the United States, nearly 4% of adults are affected by gout, and that figure continues rising steadily as dietary shifts toward purine-rich foods like red meat and alcohol make more people susceptible, while an aging population with more chronic illness including diabetes and hypertension adds further to rising case counts.

Continued research and the launch of new gout treatments are also driving market growth. Approval for biologic drugs such as pegloticase, in addition to the availability of new treatment options, has contributed to improving patient outcomes, and more recently developed drugs that address the underlying causes of gout such as the IL-1β inhibitors have been found to be successful in reducing flare-ups and protecting joints from damage.

Restraints: High treatment costs and limited insurance coverage

High prices of advanced drugs used to treat the disease remain one of the most significant limitations in the market for gout treatments. These are not affordable to all people due to the lack of medical insurance coverage of such advanced drugs or low medical insurance coverage.

The high price of these medications limits their availability especially in developing countries due to budget constraints in healthcare facilities, and the cost involved in managing gout on a long term basis discourages patient adherence to medication. This makes many patients unable to access the best medications, limiting the growth of the market.

Opportunities: Expansion of biosimilar options improving treatment access

The gout therapeutics market offers substantial opportunity through the increasing availability of biosimilars. With the expiry of patents on biologics such as pegloticase, there is increased production by pharmaceutical firms of biosimilars that present cost-effective treatment options for an expanded patient population for biologic-grade treatment of gout.

The efficacy of biosimilars is similar to that of the branded versions at a reduced cost of treatment, which becomes particularly important in the case of developing countries where expenditure on healthcare is a limiting factor. The introduction of biosimilars is going to have a positive impact on the availability of treatment options, the results of therapy, and overall market development.

Recent Developments:

• 2026: Amgen Inc. expanded access programs for biologic gout therapy (pegloticase-based treatment), improving availability for refractory gout patients in North America and Europe.

• 2026: Novartis AG advanced late-stage clinical trials of next-generation urate-lowering therapies targeting improved safety and reduced flare frequency in chronic gout patients.

• 2026: Sobi strengthened its inflammation pipeline by expanding IL-1 pathway inhibitor research, focusing on better long-term gout flare control and reduced recurrence rates.

• 2026: Sun Pharmaceutical Industries Ltd. launched new generic febuxostat formulations in emerging markets, improving affordability and increasing treatment penetration in Asia and Latin America.

Gout Therapeutics Market key players are:

• Takeda Pharmaceutical Company Limited

• Amgen Inc.

• Novartis AG

• AstraZeneca plc

• Sobi (Swedish Orphan Biovitrum AB)

• Viatris Inc.

• Dr. Reddy's Laboratories Ltd.

• Sun Pharmaceutical Industries Ltd.

• Zydus Lifesciences Ltd.

• Cipla Ltd.

• Lupin Pharmaceuticals, Inc.

• Glenmark Pharmaceuticals Ltd.

• Torrent Pharmaceuticals Ltd.

• Aurobindo Pharma Ltd.

• Hikma Pharmaceuticals PLC

• Apotex Inc.

• Endo International plc

• Pfizer Inc.

• Merck & Co., Inc.

• Regeneron Pharmaceuticals, Inc.

Gout Therapeutics Market Report Scope: